Ranbaxy Laboratories launches generic Cadeut in the American market

07 Dec 2011 Evaluate

Drug firm Ranbaxy Laboratories launched a generic version of Caduet, used for treating cardio vascular diseases, in the US market, as part of an agreement with Pfizer Inc. Caduet presently marketed by Pfizer is a fixed-dose combination of Atorvastatin-Amlodipine besylate which also contains a crystalline form of Atorvastatin. According to IMS-MAT September 2011, Caduet generated total annual sales of USD 339 million in the US.

Peers
Company Name CMP
Sun Pharma Inds. 1775.70
Dr. Reddys Lab 1207.50
Cipla 1486.50
Lupin 2058.50
Zydus Lifesciences 945.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.